Once the meniscus is reduced to its anatomical position, a non-metal anchor is placed in the tibia to hold the tension of the sutures, allowing the meniscus to heal in the correct anatomical location
It was first described in the Journal of Physiology-Paris by Sikiri and colleagues in 1993

## GHRP vs GLP-1: Head-to-Head Comparison for Bodybuilding | Parameter | GHRP-2/6, CJC-1295, Ipamorelin | Semaglutide | Tirzepatide | Retatrutide | |-----------|--------------------------------|-------------|-------------|-------------| | **Primary Mechanism** | Indirect GH release | GLP-1 receptor agonism | GLP-1 + GIP agonism | GLP-1 + GIP + Glucagon | | **Fat Loss Evidence** | Anecdotal, no Phase III trials | 1517% (STEP trials, *Nature Medicine*) | Up to 22.5% (SURMOUNT, *NEJM*) | Up to 24.2% (Phase 2, *The Lancet*) | | **Muscle Preservation** | Claimed, not proven in trials | ~6075% of loss is fat | Potentially superior (GIP effect) | Best profile (GIP + glucagon) | | **Appetite Effect** | GHRP-6 increases hunger significantly | Powerful appetite reduction | Strong appetite reduction | Strong appetite reduction | | **Visceral Fat Targeting** | Not specifically demonstrated | Demonstrated in clinical trials | Demonstrated in clinical trials | Enhanced by glucagon receptor | | **Clinical Evidence Level** | Low (small studies, animal data) | Very High (10,000+ participants) | Very High (5,000+ participants) | High (Phase 2 completed) | | **FDA Status** | Category 2 (banned) | FDA-approved | FDA-approved | Phase 3 ongoing | | **Injection Frequency** | 13x daily | Once weekly | Once weekly | Once weekly | | **Alibaba Availability** | Banned | Available | Available | Available | ## Addressing the Muscle Loss Concern: GLP-1 Peptides and Lean Mass The biggest concern bodybuilders have about GLP-1 peptides for fat loss is muscle loss

Langfristige Ergebnisse zeigen sich nach 23 Wochen regelmiger Anwendung